Everything you all need to know about Mr John A Zehner:
John Zehner, President and CEO of NukeMed, Inc.
John Zehner has over 20 years of experience in the Nuclear Medicine field. Mr. Zehner has been part of several start-ups and mergers/acquisitions in his field.
•In 1993, he was a cofounder of Northern Virginia Isotopes, Inc. which was an independent nuclear pharmacy in the Washington D.C. market. •In 1995, Mr. Zehner led the effort to form Eastern Isotopes, Inc. from three nuclear pharmacies in the Washington D.C. metro market. •In 1998, Mr. Zehner founded a cyclotron based positron emission tomography production facility to produce FDG inside Eastern Isotopes, Inc. This company ultimately grew into one of the world’s largest producers of Positron emitting radioisotopes known as IBA molecular. •In 2003, Mr. Zehner lead the effort to sell Eastern Isotopes, Inc. to IBA, S.A. a life science company located in Belgium. •In 2004, Mr. Zehner founded NukeMed, Inc. and its subsidiary, DoseShield, Inc. that was focused on the automation of radiopharmaceutical compounding. •In 2008, Mr. Zehner sold DoseShield to Positron Corporation as an earn-out sale. •In 2009, Mr. Zehner consolidated the operations of Positron Corporation into Indiana to form a pharmaceutical manufacturing arm of the company. •In 2010, Mr. Zehner opened a cGMP facility to complete the earn-out sale of DoseShield to Positron. As COO of Positron, Mr. Zehner consolidated existing operations from Texas and Canada to Indiana. Mr. Zehner formed a sales organization and transferred the automation technology to Positron from DoseShield. Mr. Zehner established a cGMP facility and management team for the manufacture of FDA approved pharmaceuticals. During Mr. Zehner’s tenure, Positron was awarded a 510K FDA recognition for a Positron Emission Tomography imaging device, began sales of the device and established a joint venture to develop radiopharmaceutical automation with Covidien, one of the world’s largest radiopharmaceutical manufacturers.
As President and COO of Eastern Isotopes, Inc., Mr. Zehner grew the company from a regional distribution pharmacy serving the Washington DC metro area to a national pharmaceutical manufacturing, imaging and distribution company serving over 26 states. Under Mr. Zehner, company sales grew from around 4 million in 1998 to over 34 million in 2003. The company grew from 3 nuclear pharmacies and 50 employees to 14 facilities consisting of pharmaceutical manufacturing plants, nuclear medicine imaging clinics and nuclear pharmacies with approximately 300 employees.
Mr. Zehner was project leader for selling Eastern Isotopes, Inc. to IBA, SA, a Belgium life science company, in 2001 with an earn-out period. The enterprise value of the sale was approximately $50 million. During the earn-out period, Mr. Zehner had advisory responsibilities for IBA S. A. affiliates in France, Italy and Belgium.
Mr. Zehner regularly presented overviews of Eastern Isotopes, Inc. and Positron to academic institutions, investors, large clients and other nuclear medicine vendors. He delivered an educational presentation to the Institute of Clinical PET (currently the Academy of Molecular Imaging) about opportunities in cyclotrons. He presented on behalf of Eastern Isotopes, Inc., who was ultimately awarded the largest contract for FDG at the time with a group purchasing organization (GPO), the GPO represented over 1500 hospitals. Eastern Isotopes, Inc. developed joint ventures with the University of West Virginia, the Medical College of Virginia and Philips (Formally ADAC) during Mr. Zehner’s tenure.
Mr. Zehner has experience that includes extensive regulatory affairs with the Nuclear Regulatory Commission (NRC), the Food and Drug Administration (FDA), the Department of Transportation (DOT) and various state pharmacy boards. He has developed and presented budgets, financial projections and market outlooks to investors and various financial institutions on numerous occasions. He has hands on experience as a nuclear pharmacist in 5 different states and as a radiation safety officer for 4 different companies, including Positron, Eastern Isotopes, Inc. and GE Healthcare (Formally Amersham). He also has direct experience as a cyclotron operator for drug manufacturing.
Mr. Zehner lives in Indianapolis, Indiana and is a guest speaker at Purdue University College of Pharmacy and a member of the American Pharmaceutical Association, the American Nuclear Society and the Society of Nuclear Medicine. Mr. Zehner is married to wife Lori with three daughters, Kayla, Paige and Maci. Mr. Zehner holds pharmacy licenses in 3 states and is recognized by the Nuclear Regulatory Commission as an authorized user and Radiation Safety officer. Mr. Zehner has a patent involving the automation of nuclear medicine products
It appears (according to the new NukeMed website) that Mr Zehner is still the CEO and President of NukeMed Inc. (Positron also have shares in NukeMed Inc.).
NukeMed, Inc. focuses on the manufacture, distribution and imaging of radiopharmaceutical products. NukeMed, Inc. will provide turnkey imaging and production facilities for Nuclear medicine, as well as, assistance with the handling and automation of radioisotopes, operation of cyclotron facilities and general distribution of radioactive material. NukeMed, Inc. offers assistance with various regulatory issues related to radioactive material, including but not limited to: the practice of pharmacy, USP-797, the Food and Drug Administration (FDA), the Department of Transportation (DOT) and the Nuclear Regulatory Commission (NRC
It appears to me if I put it all together based on todays PR and reading between the lines (you have to do that sometimes with Pat)that our Mr Zehner is still very much involved with Positron going forward and he is moving from the R&D side to actually manufacturing and bringing it to market. Very smart move since he has some pretty strong connections at Purdue University. Perdue have one of the largest Nuclear Pharmacy campuses
News 
Market Data 
Discover 
AI
